17 / 20
Page 36
allied
academies
J u n e 2 8 - 2 9 , 2 0 1 8 | A m s t e r d a m , N e t h e r l a n d s
Joint Event on
OBESITY AND WEIGHT MANAGEMENT
VACCINES AND IMMUNOLOGY
&
International Conference on
International Conference on
Asian Journal of Biomedical and Pharmaceutical Sciences
|
Volume 8
ISSN:
2249-622X
LUNG MUCOSAL DELIVERY OF
NANOCARRIER PNEUMOCOCCAL
VACCINE
Imran Saleem
Reader in Nanomedicine, Liverpool John Moores University, UK
T
here is a huge drive in the vaccine research field, pharmaceutical industry
and Bill Gates Foundation for effective targeting of dendritic cells
(DCs) to enhance the immune response and for needle-free vaccination.
The aim of this study was to adsorb pneumococcal protein (PspA), onto
poly(glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL, nanoparticles
(NPs) to target lung DCs. Further to formulate these NPs into dry powder
nanocomposite microparticles (NCMPs) suitable for pulmonary vaccine
delivery. NPs were prepared using an emulsion solvent evaporation method
and PspA was adsorbed onto the surface of NPs (100:20 [NP: PspA]). The
NPs were spray-dried in an aqueous suspension of leucine (1:1.5) to produce
NCMPs and characterised in terms of particle size, loading, cell viability,
protein stability (SDS-PAGE), integrity (circular dichroism, CD), antigenicity
(ELISA), immunization and aerosolisation studies. The NPs produced were
322.83±4.25 nm in size with PspA loading 19.68±2.74 µg/mg. The NCMPs
resulted in a fine particle fraction (FPF%) >75%. The NPs appear to be
well tolerated by DCs cell lines ≥90% cell viability) at 19.5µg/mL after 4h
exposure. SDS-PAGE, CD (α-helical decreased <13% vs. standard PspA) and
the antigenicity (>95%) confirmed that PspA was stable in both formulations
after spray-drying. The cfu in BALF of mice challenged with pneumococcal
bacteria was signifcantly less compared to PspA alone in the lungs or via
subcutaneous injection. The PspA loaded NPs were incorporated into NCMPs
having excellent aerosolisation characteristics whilst maintaining protein
activity. Hence, it may be feasible to use these carriers for pulmonary vaccine
delivery.
Imran Saleem is a reader in nanomedicine with-
in the School of Pharmacy and Biomolecular
Sciences, Liverpool John Moores University, UK.
His research is aimed at developing novel de-
livery systems for targeting therapeutic agents
to their site of action, with emphasis on lung
diseases via dry powder pulmonary delivery.
He has over 10 years’ of experience in micro/
nanoparticle formulation and drug delivery sys-
tems, and has published extensively in peer-re-
viewed journals, conference abstracts and book
chapters. His research group is focused on the
design and development of nanocarriers for de-
livery of biomacromolecules including, genes,
peptides, vaccines and drugs.
i.saleem@ljmu.ac.ukBIOGRAPHY
Imran Saleem, Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C1-002
Fig.1:
Lung mucosal delivery of nanocarrier pneumococcal vaccine.